Epidermolysis Bullosa is Estimated to Witness High Growth Owing to Opportunity in Novel Therapies Developments
Epidermolysis bullosa (EB) refers to a group of rare genetic disorders that cause easy blistering of the skin and mucous membranes from slight friction or trauma. The condition is caused by mutations in any one of at least 18 genes, which produce proteins that provide strength and anchoring roles in the epidermis and underlying basement membrane zone. The signs and symptoms of EB vary depending on the specific type and severity. Currently, there is no treatment available to cure EB. However, the available treatment options aim to manage symptoms which include wound care, pain management, surgery for certain complications, genetic counseling and preventative dental care.
The global Epidermolysis Bullosa Market is estimated to be valued at US$ 3,429.30 Mn in 2023 and is expected to exhibit a CAGR of 11% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Opportunity:
The major growth opportunity in the EB market is the development of novel therapies. Over the past few years, significant advancements have been made in developing gene, cell and drug therapies for EB. Some promising therapies under development include EB-101, Gentherapic’s topical gene therapy, Abeona’s EB-201 gene therapy, Crispr gene-editing therapies and others. These novel therapies have potential to cure EB by correcting the underlying genetic defects. With successful development and approval, these therapies can transform the treatment landscape and drive high growth of the EB market during the forecast period.
Porter’s Analysis:
Threat of new entrants: Low-medium as R&D is costly and IP rights protect drugs.
Bargaining power of buyers: Moderate-high as there are no generic substitutes yet and patients demand curative therapies.
Bargaining power of suppliers: High as there are few approved drugs and therapies and a strong clinical pipeline.
Threat of new substitutes: Low as no cure exists and demand outpaces supply.
Competitive rivalry: High as key players compete to gain approvals and market share.
SWOT Analysis:
Strengths: Growing clinical pipeline, early research success, unmet medical need.
Weaknesses: Rare disease, high costs, complex therapeutic areas involving skin and mucosal tissues.
Opportunities: Receiving orphan drug designation speeds approvals, potential for high drug prices.
Threats: Strong competition, long development timelines, failure risks in late-stage clinical trials.
Key Takeaways:
The global Epidermolysis Bullosa market is expected to witness high growth.
Regional analysis: North America currently dominates due to presence of clinical research facilities and clinical trials. However, Asia Pacific is expected to grow at fastest pace due increased diagnosis and awareness.
Key players operating in the Epidermolysis Bullosa marketare Amryt Pharma, Abeona Therapeutics, Castle Creek Pharmaceuticals, RegeneRx, Krystal Biotech, RHEACELL GmbH, Holostem Terapie Avanzate, StemRim/Shionogi, and Phoenix Tissue Repair. The key players are focused on bringing novel therapies through clinical trials and approvals to tap marketpotential.
